Ayala Pharmaceuticals Inc (AYLA)
$0.50
$0.00 (0.00%)As on 27-Jan-2023 09:30EDT
Market cap
$8 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-38 Mln
-
ROE
-1.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.1
-
Face value
--
-
Shares outstanding
14,820,700
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ayala Pharmaceuticals Inc (AYLA)
| 25.9 | 22.8 | -21.3 | -91.4 | -- | -- | -- |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
Ayala Pharmaceuticals Inc (AYLA)
| -95.3 | -22.6 |
|
S&P Small-Cap 600
| -17.4 | 25.3 |
|
BSE Sensex
| 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ayala Pharmaceuticals Inc (AYLA)
|
0.5 | 7.9 | 1.7 | -30.4 | -1,803.2 | -184.5 | -- | 1.0 |
| 15.0 | 521.5 | 68.2 | -29.0 | -35.9 | -88.3 | -- | 18.0 | |
| 36.0 | 1,218.6 | 0.0 | -61.6 | -- | -33.1 | -- | 7.0 | |
| 11.2 | 299.9 | 19.6 | -176.7 | -839.0 | -- | -- | 2.4 |
Shareholding Pattern
View DetailsAbout Ayala Pharmaceuticals Inc (AYLA)
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent,... selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel. Read more
-
Pres, CEO & Director
Dr. Roni Mamluk M.D., Ph.D.
-
Pres, CEO & Director
Dr. Roni Mamluk M.D., Ph.D.
-
Headquarters
Rehovot
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ayala Pharmaceuticals Inc (AYLA)
What is the current share price of Ayala Pharmaceuticals Inc (AYLA) Today?
The share price of Ayala Pharmaceuticals Inc (AYLA) is $0.50 (NASDAQ) as of 27-Jan-2023 09:30 EDT. Ayala Pharmaceuticals Inc (AYLA) has given a return of -91.42% in the last 1 years.
What is the current PB & PE ratio of Ayala Pharmaceuticals Inc (AYLA)?
Since, TTM earnings of Ayala Pharmaceuticals Inc (AYLA) is negative, P/E ratio is not available.
The P/B ratio of Ayala Pharmaceuticals Inc (AYLA) is 1.02 times as on 02-Feb-2023, a 78 discount to its peers’ median range of 4.72 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-2.96
|
3.49
|
|
2020
|
-3.65
|
2.86
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2021
|
-2.96
|
3.49
|
What is the 52 Week High and Low of Ayala Pharmaceuticals Inc (AYLA)?
The 52-week high and low of Ayala Pharmaceuticals Inc (AYLA) are Rs -- and Rs -- as of 13-Jun-2026.
What is the market cap of Ayala Pharmaceuticals Inc (AYLA)?
Ayala Pharmaceuticals Inc (AYLA) has a market capitalisation of $ 8 Mln as on 02-Feb-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Ayala Pharmaceuticals Inc (AYLA)?
Before investing in Ayala Pharmaceuticals Inc (AYLA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.